Browse studies

Find your next paid study

105 recruiting studies matching your filters

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients …

Lung CancerLung Cancer MetastaticBrain Metastases+1 more

Estimated

~$10 – $6,250

University of California, DavisNCT05452005

Phase 1

IFN-y PET Imaging: Bench to Bedside

The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy …

Non Small Cell Lung Cancer

Estimated

~$10 – $7,500

Nerissa T. ViolaNCT06439914

Phase 2

A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus (VS) Standard-Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage 2A/B Non-Small Cell Lung Cancer

The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed b…

Non Small Cell Lung Cancer Stage

Estimated

~$10 – $6,250

University of Kansas Medical CenterNCT04992780

Phase 1

A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC

The goal of this open-label, Phase 1 clinical trial is to determine the safety of TTFields started concurrently with SOC chemoradiation and during consolidatio…

Non Small Cell Lung Cancer

Estimated

~$10 – $6,250

University of UtahNCT06124118

Phase 2

Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

Non Small Cell Lung Cancer

Estimated

~$10 – $7,500

Diwakar DavarNCT05669846

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despit…

Non Small Cell Lung CancerEsophageal CancerGastric Cancer+3 more

Estimated

~$10 – $750

University of Missouri-ColumbiaNCT03551951

PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are goi…

Non Small Cell Lung CancerHealthy

Estimated

~$10 – $1,050

OncoHost Ltd.NCT05736029

Phase 1

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recomb…

Triple Negative Breast CancerHormone-Resistant Breast CancerNon Small Cell Lung Cancer+1 more

Estimated

~$10 – $8,750

A&G Pharmaceutical Inc.NCT05627960

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical tria…

Cancer, MetastaticCancerCancer of Pancreas+40 more

Estimated

~$10 – $1,050

Massive Bio, Inc.